

**Supplemental Figure. Prescribing patterns for treatment naïve PLWH in the CNICS cohort initiating ART between 2007 – 2015 (Supplemental)**

|  |  |
| --- | --- |
| A | Dolutegravir/abacavir/lamivudine |
| B | Atazanavir/ritonavir/emtricitabine/tenofovir/r |
| C | Darunavir/ritonavir/emtricitabine/tenofovir |
| D | Dolutegravir/emtricitabine/tenofovir |
| E | Efavirenz/emtricitabine/tenofovir |
| F | Elvitegravir/cobicistat/emtricitabine/tenofovir |
| G | Raltegravir/emtricitabine/tenofovir |
| H | Rilpivirine/emtricitabine/tenofovir |
| O | Other |

1. Lundgren, J.D., et al., *Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection.* N Engl J Med, 2015. **373**(9): p. 795-807.

2. Cohen, M.S., et al., *Antiretroviral Therapy for the Prevention of HIV-1 Transmission.* N Engl J Med, 2016.

3. DHHS. *Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents.*

. [cited 2016 August 10]; Available from: http://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv-guidelines/0.

4. Gunthard, H.F., et al., *Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2016 Recommendations of the International Antiviral Society-USA Panel.* Jama, 2016. **316**(2): p. 191-210.

5. Clotet, B., et al., *Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study.* Lancet, 2014. **383**(9936): p. 2222-31.

6. Walmsley, S.L., et al., *Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection.* N Engl J Med, 2013. **369**(19): p. 1807-18.

7. Sax, P.E., et al., *Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials.* Lancet, 2015. **385**(9987): p. 2606-15.

8. Stellbrink, H.J., et al., *Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study.* Clin Infect Dis, 2010. **51**(8): p. 963-72.

9. Wohl, D., et al., *Brief Report: A Randomized, Double-Blind Comparison of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate, Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine for Initial HIV-1 Treatment: Week 96 Results.* J Acquir Immune Defic Syndr, 2016. **72**(1): p. 58-64.

10. Castillo-Mancilla, J.R., et al., *Minorities remain underrepresented in HIV/AIDS research despite access to clinical trials.* HIV Clin Trials, 2014. **15**(1): p. 14-26.

11. Nieuwkerk, P.T., et al., *LImited patient adherence to highly active antiretroviral therapy for hiv-1 infection in an observational cohort study.* Archives of Internal Medicine, 2001. **161**(16): p. 1962-1968.

12. Al-Dakkak, I., et al., *The impact of specific HIV treatment-related adverse events on adherence to antiretroviral therapy: a systematic review and meta-analysis.* AIDS Care, 2013. **25**(4): p. 400-14.

13. Eaton, E.F., et al., *Unanticipated effects of new drug availability on antiretroviral durability: Implications for Comparative Effectiveness Research*. 2016: Open Forum Infectious Diseases

14. Sheth, A.N., et al., *Antiretroviral regimen durability and success in treatment-naive and treatment-experienced patients by year of treatment initiation, United States, 1996-2011.* J Acquir Immune Defic Syndr, 2015.

15. Slama, L., et al., *Increases in duration of first highly active antiretroviral therapy over time (1996-2009) and associated factors in the Multicenter AIDS Cohort Study.* J Acquir Immune Defic Syndr, 2014. **65**(1): p. 57-64.

16. Di Biagio, A., et al., *Discontinuation of Initial Antiretroviral Therapy in Clinical Practice: Moving Toward Individualized Therapy.* J Acquir Immune Defic Syndr, 2016. **71**(3): p. 263-71.

17. Kitahata, M.M., et al., *Cohort profile: the Centers for AIDS Research Network of Integrated Clinical Systems.* Int J Epidemiol, 2008. **37**(5): p. 948-55.

18. Markowitz, M., et al., *Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study.* J Acquir Immune Defic Syndr, 2007. **46**(2): p. 125-33.

19. Arribas, J.R., et al., *The MONET trial: week 144 analysis of the efficacy of darunavir/ritonavir (DRV/r) monotherapy versus DRV/r plus two nucleoside reverse transcriptase inhibitors, for patients with viral load < 50 HIV-1 RNA copies/mL at baseline.* HIV Med, 2012. **13**(7): p. 398-405.

20. McKinnell, J.A., et al., *Antiretroviral prescribing patterns in treatment-naive patients in the United States.* AIDS Patient Care STDS, 2010. **24**(2): p. 79-85.

21. Cotte, L., et al., *Effectiveness and tolerance of single tablet versus once daily multiple tablet regimens as first-line antiretroviral therapy - Results from a large french multicenter cohort study.* PLoS One, 2017. **12**(2): p. e0170661.

22. Robison, L.S., et al., *Short-term discontinuation of HAART regimens more common in vulnerable patient populations.* AIDS Res Hum Retroviruses, 2008. **24**(11): p. 1347-55.

23. Hughes, A.J., et al., *Discontinuation of antiretroviral therapy among adults receiving HIV care in the United States.* J Acquir Immune Defic Syndr, 2014. **66**(1): p. 80-9.

24. Centers for Disease Control and Prevention. *Reportable STDs in Young People 15-24 Years of Age, by State*. 2013; Available from: https://www.cdc.gov/std/stats/by-age/15-24-all-stds/default.htm.

25. The Centers for Disease Control. *HIV in the United States: At A Glance*. July 2015 [cited 2016 February 26]; Available from: http://www.cdc.gov/hiv/pdf/statistics\_basics\_ataglance\_factsheet.pdf.